AffaMed Therapeutics

Anticipating more hardships ahead, innovative drug makers are taking to the road and talking with potential investors from some non-conventional sectors, noted executives at the inaugural Asia Bio Par

Amid increasingly hot competition for oncology drugs, a new crop of biotechs are looking at CNS conditions and AffaMed Therapeutics , backed by CBC group (formerly C-Bridge Capital) has licensed excl

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sol-Gel Hopes To Bring PellePharm’s Pat

VistaGen Therapeutics, Inc. has rebounded from clinical development setbacks before, but investors imposed a severe penalty on the South San Francisco biotech on 22 July following its pre-market anno